{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000922","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.494698+00:00","generated_at":"2026-05-16T01:38:27.331881+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"DOJ closes inquiry into Cassava Sciences; ends all government investigations","bullets":["DOJ Fraud Section closed previously-disclosed inquiry into research misconduct allegations.","The related indictment in United States v. Wang was dismissed with prejudice on Oct 23, 2025.","Company previously settled SEC negligence charges in Sept 2024 with monetary penalty.","CEO Richard Barry says company remains focused on developing treatment for TSC-related epilepsy.","No further government investigations pending against Cassava Sciences."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000922","json":"https://secwatch.observer/filing/0001171843-26-000922.json","markdown":"https://secwatch.observer/filing/0001171843-26-000922.md","text":"https://secwatch.observer/filing/0001171843-26-000922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184326000922/0001171843-26-000922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184326000922/f8k_021926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:38:27.331881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}